Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharmaceuticals and GlaxoSmithKline (GSK) have received the US Food and Drug Administration (FDA) approval for Potiga (ezogabine) Tablets as an adjunctive medicine for patients aged 18 years and above suffering from partial-onset seizures.
Subscribe to our email newsletter
Three controlled clinical trails comprising 1,239 adult patients have established the efficacy of ezogabine as adjunctive therapy in partial onset seizures.
The companies plan to introduce the product by the end of the year in the US.
The FDA has recommended that ezogabine be scheduled as a controlled substance under the Controlled Substances Act (CSA).
Valeant Research and Development head Susan Hall said they are so pleased to reach such an important milestone with the US approval of Potiga by the FDA.
"We believe this product will play a needed role in the management of partial onset seizures in appropriate patients who are uncontrolled on their current medications," Hall said.